Sign in
CompletedNo phase

Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the site
Trial code
Status
Completed
People taking part
100 people enrolled
Started
6 Jun 2022
Ended
28 Feb 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Metagenomic Deep Sequencing (MDS)
  • Standard of Care (SOC)
Record updated
26 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Presumed infectious anterior uveitis, or intermediate uveitis, or posterior uveitis, or panuveitis
  • Presumed post-operative endophthalmitis
  • Unilateral or bilateral
  • 18 years and older

Who cannot take part

  • Age < 18 years of age
  • Insufficient specimen for MDS
  • Pregnancy
  • Unable to consent

Where in United States

  • University of California, San Francisco (UCSF)San Francisco, United States

About the trial

What the trial wants to find out

This is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility criteria will be randomized to receive MDS testing results or not to receive MDS testing results. All patients will receive standard-of-care testing to guide management. Enrolled patients will be followed at week 2, week 3-6 (randomization visit), and at 4 weeks after the randomization visit. The proportions of patients who received the appropriate therapy and the proportions of patients with improved outcome will be compared between arms. Patient quality of life, MDS performance, and the provider certainly of belief will be collected.

The 2 groups in the trial

  • Standard of CareExisting treatment, for comparison

    Patients enrolled in the trial and randomized to the standard of care (SOC) arm will undergo standard of care testing.

    Treatment: Standard of Care (SOC)

  • MDSTreatment being tested

    Patients enrolled in the trial and randomized to the MDS arm will undergo standard of care testing and MDS testing.

    Treatment: Metagenomic Deep Sequencing (MDS)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
26 June 2026